Transformation of advanced lung adenocarcinoma to acquired T790M resistance mutation adenosquamous carcinoma following tyrosine kinase inhibitor: a case report

Liu, Qinghan; Wu, Lin; Zhang, Suning

doi:10.1177/0300891620973262

Cited by 6 publications

(3 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Adeno-squamous transformation, a change in histology from adenocarcinoma to squamous cell carcinoma, has been observed in two (22%) of nine patients with KRAS G12C -mutant NSCLC following acquired resistance to adagrasib, in the absence of genomic resistance mechanisms described previously 106 . Similar histological transformation has been associated with resistance to EGFR inhibitors 119,120 .…”

Section: Emt and Adeno-squamous Transformationmentioning

confidence: 56%

The current state of the art and future trends in RAS-targeted cancer therapies

et al. 2022

View full text Add to dashboard Cite

show abstract

Section: Emt and Adeno-squamous Transformationmentioning

confidence: 56%

The current state of the art and future trends in RAS-targeted cancer therapies

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Combined with chemotherapy, it can play a synergistic role, improve the immune function of patients and promote the anti-tumor effect. 26,27 The results of this study also show that EGFR-TKI targeted combined chemotherapy is associated with improved levels of tumor markers and improved treatment effect. Xu A et al 28 showed that EGFR-TKI targeted therapy applied to patients with advanced EGFR mutant NSCLC can downregulate the levels of CEA, CYFRA21-1 and MMP-9, effectively inhibit angiogenesis and enhance the immune function of patients.…”

Section: Discussionmentioning

confidence: 53%

Effects of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) targeted combined chemotherapy on immune function, tumor markers and oxidative stress in patients with stage IV lung adenocarcinoma

Kun¹,

Wu²,

Chen

2023

Pak J Med Sci

View full text Add to dashboard Cite

Objective: To investigate the effects of EGFR-TKI combined chemotherapy on immune function, tumor markers and oxidative stress in patients with stage-IV lung adenocarcinoma. Methods: This retrospective observational study included 116 patients with stage-IV lung adenocarcinoma, treated in The First Affiliated Hospital of Soochow University from January 2021 to January 2022. According to the treatment records, 60 patients that received pemetrexed + cisplatin for four courses were set as a Control-group and 56 patients that received EGFR-TKI + pemetrexed + cisplatin for four courses were set as an Observation-group. Changes in immune function, tumor marker levels and oxidative stress level in the two groups were analyzed and compared. Results: After the treatment, levels of CD3+, CD4+, IgG and IgM in the Control-group were significantly lower than those before the treatment. EGFR-TKI + pemetrexed + cisplatin resulted in levels of CD3+, CD4+, IgG and IgM higher than before the treatment, and compared to the Control-group (p<0.001). After the treatment, the levels of NSE, serum CEA, serum CA125, CYFEA21-1 in both groups were significantly lower than those before treatment, and lower in the Observation-group (p<0.001). After the treatment, VEGF and MMP9 levels in both groups were significantly lower than those before treatment, and markedly lower in the Observation-group (p<0.001). Conclusion: Compared with systemic chemotherapy, EGFR-TKI targeted combined chemotherapy for stage-IV lung adenocarcinoma is associated with enhanced immune function of patients. It more effectively inhibits the growth and proliferation of tumor cells and reduces the level of oxidative stress. doi: https://doi.org/10.12669/pjms.39.3.7397 How to cite this: Kun Y, Wu J, Chen S. Effects of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) targeted combined chemotherapy on immune function, tumor markers and oxidative stress in patients with stage IV lung adenocarcinoma. Pak J Med Sci. 2023;39(3):742-746. doi: https://doi.org/10.12669/pjms.39.3.7397 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

show abstract

“…EGFR -TKIs are recommended for patients with NSCLC having EGFR mutations ( 10 ). Data regarding treatment effectiveness for EGFR -TKIs in NSCLC patients with non-resistant, uncommon EGFR mutations are limited.…”

Section: Discussionmentioning

confidence: 99%

Case Report: Durable partial response to icotinib plus crizotinib in a lung adenocarcinoma patient with double uncommon EGFR G719D/L861Q mutations and an acquired novel CUX1-MET fusion

Tang

Deng

et al. 2022

Front. Oncol.

View full text Add to dashboard Cite

Non-small cell lung cancer (NSCLC) patients harboring MET exon 14 skipping or high MET amplification display a high rate of response to MET inhibitors. However, MET fusions in NSCLC have rarely been revealed. In this report, a 63-year-old woman with lung adenocarcinoma (LADC), harboring EGFR exon 18 G719D and exon 21 L861Q mutations, received first-generation, EGFR-tyrosine kinase inhibitor (TKI) icotinib therapy. Next generation sequencing (NGS) results only displayed an EGFR T790M point mutation following icotinib resistance. Thus, the patient was treated with osimertinib and achieved a stable disease (SD). However, disease progressed after 15 months and a novel MET fusion (CUX1 exon14-MET exon15) in addition to EGFR G719D/L861Q mutations were simultaneously detected in a tissue biopsy sample. After more than nine months, the patient subsequently achieved a PR with the combination of icotinib and crizotinib. To our knowledge, this is the first case of LADC patient displaying the presence of EGFR double uncommon mutations and an acquired novel CUX1-MET fusion that has benefited from icotinib plus crizotinib treatment. Following nine months of PR with icotinib plus crizotinib, the patient, until the time of publication, is exhibiting stable disease. The results suggest that the CUX1-MET fusion may be sensitive to crizotinib, although previous reports indicated that some MET fusion cases did not respond to crizotinib. Given this disparity, distinguishing MET fusion partners when crizotinib is used in LADC treatment is also very important.

show abstract

Transformation of advanced lung adenocarcinoma to acquired T790M resistance mutation adenosquamous carcinoma following tyrosine kinase inhibitor: a case report

Cited by 6 publications

References 14 publications

The current state of the art and future trends in RAS-targeted cancer therapies

The current state of the art and future trends in RAS-targeted cancer therapies

Effects of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) targeted combined chemotherapy on immune function, tumor markers and oxidative stress in patients with stage IV lung adenocarcinoma

Case Report: Durable partial response to icotinib plus crizotinib in a lung adenocarcinoma patient with double uncommon EGFR G719D/L861Q mutations and an acquired novel CUX1-MET fusion

Contact Info

Product

Resources

About